TetraLogic Pharmaceuticals, which is developing small molecule therapeutics for the treatment of cancer, announced terms for its IPO on Wednesday. The Malvern, PA-based company plans to raise $90 million by offering 6.4 million shares at a price range of $13 to $15. At the midpoint of the proposed range, TetraLogic Pharmaceuticals would command a market value of $270 million.
TetraLogic Pharmaceuticals, which was founded in 2001, plans to list on the NASDAQ under the symbol TLOG. The company initially filed confidentially on September 16, 2013. Oppenheimer & Co., Guggenheim Securities and Needham & Co. are the joint bookrunners on the deal.
